Sinopep-Allsino Biopharmaceutical Co. Ltd. A Working Capital to Net Assets Ratio
Sinopep-Allsino Biopharmaceutical Co. Ltd. A working capital to net assets ratio. Sinopep-Allsino Biopharmaceutical Co. Ltd. A (688076) has a Working Capital to Net Assets ratio of 10.2% as of June 2026. Working capital of CN¥317.16 Million (current assets of CN¥2.63 Billion minus current liabilities of CN¥2.31 Billion) is measured against net assets of CN¥3.10 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check Sinopep-Allsino Biopharmaceutical Co. Lt tangible equity quality to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Sinopep-Allsino Biopharmaceutical Co. Ltd. A (2013–2025)
Working capital to net assets ratio of Sinopep-Allsino Biopharmaceutical Co. Ltd. A from 2013 to 2025. This chart shows how Sinopep-Allsino Biopharmaceutical Co. Ltd. A's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2013 to 2025. As of June 2026, the ratio stands at 10.2%, reflecting working capital of CN¥317.16 Million against net assets of CN¥3.10 Billion CNY. See operational self-sufficiency of Sinopep-Allsino Biopharmaceutical Co. Lt to measure how many days the company can operate on defensive assets alone.
Sinopep-Allsino Biopharmaceutical Co. Ltd. A Working Capital to Net Assets Ratio by Year (2013–2025)
Sinopep-Allsino Biopharmaceutical Co. Ltd. A working capital to net assets ratio by year from 2013 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Sinopep-Allsino Biopharmaceutical Co. Ltd. A from 2013 to 2025, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see 688076 asset base.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 11.6% | CN¥349.12 Million | CN¥3.00 Billion | CN¥2.51 Billion | CN¥2.16 Billion | ▲ +2.2 pp |
| 2024 | 9.4% | CN¥252.82 Million | CN¥2.68 Billion | CN¥2.01 Billion | CN¥1.75 Billion | ▼ -14.4 pp |
| 2023 | 23.8% | CN¥521.43 Million | CN¥2.19 Billion | CN¥1.49 Billion | CN¥973.34 Million | ▼ -2.2 pp |
| 2022 | 26.0% | CN¥501.15 Million | CN¥1.92 Billion | CN¥1.05 Billion | CN¥551.32 Million | ▼ -19.8 pp |
| 2021 | 45.8% | CN¥828.71 Million | CN¥1.81 Billion | CN¥1.10 Billion | CN¥275.40 Million | ▲ +34.9 pp |
| 2020 | 10.9% | CN¥105.70 Million | CN¥966.02 Million | CN¥487.91 Million | CN¥382.21 Million | ▲ +15.8 pp |
| 2019 | -4.8% | CN¥-40.56 Million | CN¥838.98 Million | CN¥293.73 Million | CN¥334.30 Million | ▼ -18.5 pp |
| 2018 | 13.7% | CN¥107.63 Million | CN¥785.38 Million | CN¥357.67 Million | CN¥250.04 Million | ▲ +45.1 pp |
| 2017 | -31.4% | CN¥-100.93 Million | CN¥321.20 Million | CN¥183.31 Million | CN¥284.24 Million | ▲ +264.9 pp |
| 2016 | -296.3% | CN¥-103.57 Million | CN¥34.95 Million | CN¥21.59 Million | CN¥125.16 Million | ▼ -196.3 pp |
| 2015 | -100.0% | CN¥-73.30 Million | CN¥73.32 Million | CN¥50.06 Million | CN¥123.35 Million | ▼ -879.9 pp |
| 2014 | 779.9% | CN¥-167.46 Million | CN¥-21.47 Million | CN¥5.59 Million | CN¥173.05 Million | ▲ +4860.3 pp |
| 2013 | -4080.4% | CN¥-150.38 Million | CN¥3.69 Million | CN¥12.74 Million | CN¥163.12 Million | — |